David Cade

机构：Epix Pharmaceuticals (United States)

发表论文 117 篇 · 总被引 1231 次 · h-index 15

代表论文

Real world experience with [99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry (2024 · EJNMMI Reports · 被引 7)
STARBURST: Phase 2 Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of Carbonic Anhydrase IX (CAIX) (2025 · International Journal of Radiation Oncology*Biology*Physics · 被引 1)
ProstACT GLOBAL: A phase 3 study of 177 Lu-rosopatamab (TLX591) with and without the best standard of care for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug. (2025 · Journal of Clinical Oncology · 被引 1)
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug. (2024 · Journal of Clinical Oncology · 被引 1)
Reimagining Section 94.1: The Offshore Investment Fund Property Rule (2021 · Canadian Tax Journal/Revue fiscale canadienne · 被引 1)
Theranostic Potential of 177Lu-TLX591 with Best Standard-of-Care and 68Ga-PSMA-11 PET for Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 1 ProstACT SELECT Trial (2026 · Cancers)